Skip to main content
Top
Published in: Cancer Causes & Control 7/2007

01-09-2007 | Original Paper

Prospective case–control study of nonfatal cancer preceding the diagnosis of parkinson’s disease

Authors: Jane A. Driver, Tobias Kurth, Julie E. Buring, J. Michael Gaziano, Giancarlo Logroscino

Published in: Cancer Causes & Control | Issue 7/2007

Login to get access

Abstract

Objective

Prior studies suggest a decreased frequency of cancer in patients with Parkinson’s disease (PD). We conducted a nested case–control study to estimate the association between the diagnosis of PD and a history of preceding cancer.

Methods

Our case–control study was nested within a prospective cohort of 22,071 US male physicians. During 22 years of follow-up, 487 incident cases of PD were identified and matched by age to 487 controls. We then evaluated a history of cancer prior to the index date that was confirmed by medical record review.

Results

The frequency of any cancer was less in cases (13.1%) than in controls (14.8%). There was an inverse relationship between overall cancer (odds ratio [OR] = 0.83; 95% CI, 0.57–1.21), smoking-related (OR = 0.74; 95% CI, 0.35–1.57), and non-smoking-related cancer (OR = 0.88; 95% CI, 0.59–1.32) and the subsequent development of PD. Smoking significantly modified the relationship between PD and smoking-related cancer (p interaction = 0.002). PD cases who smoked had an OR of 0.32 (95% CI, 0.11–0.89) for smoking-related cancer. In contrast, PD cases who never smoked had an OR of 6.85 (95% CI, 0.83–56.39).

Conclusions

Our data suggest that the frequency of cancer preceding the diagnosis of PD is decreased. Smoking status prior to PD or cancer diagnosis significantly modified the association between smoking-related cancer and PD.
Literature
1.
go back to reference Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52:395–398PubMed Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52:395–398PubMed
2.
go back to reference Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310:1500–1501PubMed Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310:1500–1501PubMed
3.
go back to reference Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) A typical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205PubMedCrossRef Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) A typical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205PubMedCrossRef
4.
go back to reference Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247:429–434PubMedCrossRef Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247:429–434PubMedCrossRef
5.
go back to reference Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509PubMedCrossRef Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509PubMedCrossRef
6.
go back to reference Pritchard PB 3rd, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23:215–222PubMed Pritchard PB 3rd, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23:215–222PubMed
7.
go back to reference Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case–control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37:226–232PubMed Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case–control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37:226–232PubMed
8.
go back to reference West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28:348–352PubMedCrossRef West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28:348–352PubMedCrossRef
9.
go back to reference Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA (2002) Nonfatal cancer preceding Parkinson’s disease: a case–control study. Epidemiology 13:157–164PubMedCrossRef Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA (2002) Nonfatal cancer preceding Parkinson’s disease: a case–control study. Epidemiology 13:157–164PubMedCrossRef
10.
go back to reference Olsen JH, Friis S, Frederiksen K (2006) Malignant Melanoma and other types of cancer preceding Parkinson Disease. Epidemiology 17:582–587PubMedCrossRef Olsen JH, Friis S, Frederiksen K (2006) Malignant Melanoma and other types of cancer preceding Parkinson Disease. Epidemiology 17:582–587PubMedCrossRef
11.
go back to reference D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, Savettieri G (2004) Tumor diagnosis preceding Parkinson’s disease: a case–control study. Mov Disord 19:807–811PubMedCrossRef D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, Savettieri G (2004) Tumor diagnosis preceding Parkinson’s disease: a case–control study. Mov Disord 19:807–811PubMedCrossRef
12.
go back to reference Final report on the aspirin component of the ongoing Physicians’ Health Study (1989) Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 321:129–135 Final report on the aspirin component of the ongoing Physicians’ Health Study (1989) Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 321:129–135
13.
go back to reference Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145–1149PubMedCrossRef Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145–1149PubMedCrossRef
14.
go back to reference Christen WG, Gaziano JM, Hennekens CH (2000) Design of Physicians’ Health Study II – a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10:125–134PubMedCrossRef Christen WG, Gaziano JM, Hennekens CH (2000) Design of Physicians’ Health Study II – a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10:125–134PubMedCrossRef
15.
go back to reference The health consequences of smoking: cancer: a report of the surgeon general (1982) In: Shopland DR (ed) Centers for disease control and prevention (CDC), Office on Smoking and Health, pp 5–6 The health consequences of smoking: cancer: a report of the surgeon general (1982) In: Shopland DR (ed) Centers for disease control and prevention (CDC), Office on Smoking and Health, pp 5–6
16.
go back to reference Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284PubMedCrossRef Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284PubMedCrossRef
17.
go back to reference Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96PubMedCrossRef Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96PubMedCrossRef
18.
go back to reference Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007PubMedCrossRef Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007PubMedCrossRef
19.
go back to reference Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC et al (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 339:1375–1377PubMedCrossRef Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC et al (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 339:1375–1377PubMedCrossRef
20.
go back to reference Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238PubMedCrossRef Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238PubMedCrossRef
21.
go back to reference Lim KL, Dawson VL, Dawson TM (2003) The cast of molecular characters in Parkinson’s disease: felons, conspirators, and suspects. Ann N Y Acad Sci 991:80–92PubMedCrossRef Lim KL, Dawson VL, Dawson TM (2003) The cast of molecular characters in Parkinson’s disease: felons, conspirators, and suspects. Ann N Y Acad Sci 991:80–92PubMedCrossRef
22.
go back to reference McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179:38–46PubMedCrossRef McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179:38–46PubMedCrossRef
23.
go back to reference McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56:149–162PubMedCrossRef McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56:149–162PubMedCrossRef
24.
go back to reference Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8:313–317PubMed Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8:313–317PubMed
25.
go back to reference Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Maraganore DM, Rocca WA (2005) Education and occupations preceding Parkinson disease: a population-based case–control study. Neurology 65:1575–1583PubMedCrossRef Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Maraganore DM, Rocca WA (2005) Education and occupations preceding Parkinson disease: a population-based case–control study. Neurology 65:1575–1583PubMedCrossRef
26.
go back to reference Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2005) Physical activity and the risk of Parkinson disease. Neurology 64:664–669PubMed Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2005) Physical activity and the risk of Parkinson disease. Neurology 64:664–669PubMed
27.
go back to reference Camargo CA Jr, Hennekens CH, Gaziano JM, Glynn RJ, Manson JE, Stampfer MJ (1997) Prospective study of moderate alcohol consumption and mortality in US male physicians. Arch Intern Med 157:79–85PubMedCrossRef Camargo CA Jr, Hennekens CH, Gaziano JM, Glynn RJ, Manson JE, Stampfer MJ (1997) Prospective study of moderate alcohol consumption and mortality in US male physicians. Arch Intern Med 157:79–85PubMedCrossRef
28.
go back to reference de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63:1240–1244PubMed de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63:1240–1244PubMed
29.
go back to reference Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220PubMed Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220PubMed
30.
go back to reference Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022CrossRef Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022CrossRef
Metadata
Title
Prospective case–control study of nonfatal cancer preceding the diagnosis of parkinson’s disease
Authors
Jane A. Driver
Tobias Kurth
Julie E. Buring
J. Michael Gaziano
Giancarlo Logroscino
Publication date
01-09-2007
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 7/2007
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9005-9

Other articles of this Issue 7/2007

Cancer Causes & Control 7/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine